Celcuity Inc(CELC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CELC Celcuity Inc

休市中 07-02 16:00:00 EDT

107.95

+3.46

+3.31%

盘后107.95

+0.000.00%

19:50 EDT

最高108.32	最低102.62	成交量104.43万
今开105.84	昨收104.49	日振幅5.46%
总市值52.64亿	流通市值32.00亿	总股本4,877万
成交额1.11亿	换手率3.52%	流通股本2,965万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CELC","market":"US","secType":"STK","nameCN":"Celcuity Inc","latestPrice":107.95,"timestamp":1783022400000,"preClose":104.49,"halted":0,"volume":1044285,"hourTrading":{"tag":"盘后","latestPrice":107.95,"preClose":107.95,"latestTime":"19:50 EDT","volume":441121,"amount":47618757.04,"timestamp":1783036228888,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.033113216575748956,"floatShares":29646700,"shares":48766288,"eps":-3.88803,"marketStatus":"休市中","change":3.46,"latestTime":"07-02 16:00:00 EDT","open":105.84,"high":108.32,"low":102.62,"amount":111230325.0333,"amplitude":0.054551,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.88803,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":104.49,"preHourTrading":{"tag":"盘前","latestPrice":105.99,"preClose":104.49,"latestTime":"09:29 EDT","volume":55,"amount":5782.028175,"timestamp":1782998999919,"change":1.5,"changeRate":0.014355,"amplitude":0.022777},"postHourTrading":{"tag":"盘后","latestPrice":107.95,"preClose":107.95,"latestTime":"19:50 EDT","volume":441121,"amount":47618757.04,"timestamp":1783036228888,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7221945759621551,"impliedVol":0.7742,"impliedVolPercentile":0.5418},"requestUrl":"/m/hq/s/CELC","defaultTab":"news","newsList":[{"id":"1187497120","title":"Celcuity Inc. 定价增发5亿美元、2032年到期的0.25%可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1187497120","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187497120?lang=zh_cn&edition=full","pubTime":"2026-06-04 10:23","pubTimestamp":1780539808,"startTime":"0","endTime":"0","summary":"6月3日 - 生物技术公司 Celcuity Inc. 宣布，已为其增发的2032年到期、利率为0.250%的可转换优先票据完成定价。此次发行规模最终确定为5亿美元。\n该笔票据的发行规模较原计划有所扩大，凸显了市场对其融资条款的认可。可转换票据为投资者提供了未来将债务转换为公司股权的选择权，是成长型公司常见的融资工具之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187515046","title":"Celcuity Inc宣布公开发行2032年到期的可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1187515046","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187515046?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:39","pubTimestamp":1780486794,"startTime":"0","endTime":"0","summary":"Celcuity Inc于6月3日宣布，将公开发行一批于2032年到期的可转换优先票据。此举旨在为公司运营及战略发展募集资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199488490","title":"异动解读｜Celcuity盘中下跌23.24%，III期VIKTORIA-1临床数据公布后股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1199488490","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199488490?lang=zh_cn&edition=full","pubTime":"2026-06-03 00:20","pubTimestamp":1780417249,"startTime":"0","endTime":"0","summary":"6月2日，Celcuity盘中下跌23.24%，报93.69美元/股，成交额3.2亿美元。消息面上，公司通过SEC文件公布了III期VIKTORIA-1试验PIK3CA突变队列结果：Gedatolisib三联疗法中位无进展生存期为11.1个月，对照组Alpelisib联合Fulvestrant为5.6个月；安全性方面不良事件多为低级别。FDA已授予其新药申请优先审评资格，PDUFA目标日期定为7月17日。尽管临床数据及监管进展积极，股价仍大幅回落，提示市场此前或已充分定价甚至对数据抱有更高预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169917585","title":"Celcuity公布III期VIKTORIA-1试验PIK3CA突变队列结果 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1169917585","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169917585?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:34","pubTimestamp":1780403640,"startTime":"0","endTime":"0","summary":"Celcuity公司近期通过提交给美国证券交易委员会的文件，公布了其关键III期VIKTORIA-1临床试验中针对PIK3CA突变患者队列的详细数据。安全性方面，gedatolisib相关治疗方案普遍耐受性良好，报告的大多数不良事件为低级别。美国食品药品监督管理局已授予Celcuity公司gedatolisib的新药申请优先审评资格，并设定了处方药用户付费法案目标日期为2026年7月17日。公司表示，若获得FDA批准，正按计划推进gedatolisib在2026年第三季度的商业化上市准备工作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107864078","title":"FDA授予Celcuity公司Gedatolisib新药申请优先审评资格；PDUFA目标日期定于2026年7月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=1107864078","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107864078?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:16","pubTimestamp":1780402573,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已授予Celcuity公司旗下药物Gedatolisib的新药申请（NDA）优先审评资格。根据提交至美国证券交易委员会（SEC）的文件，该申请的处方药使用者付费法案（PDUFA）目标日期设定为2026年7月17日。此举标志着该药物在监管审批流程中迈出了关键一步，有望加速其上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134324033","title":"Celcuity：Gedatolisib三联疗法对比Alpelisib联合Fulvestrant，中位无进展生存期达11.1个月 vs 5.6个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1134324033","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134324033?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:15","pubTimestamp":1780402521,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，Celcuity Inc 公布的数据显示，其Gedatolisib三联疗法在关键试验中取得了显著成果。\n该疗法展现出的中位无进展生存期达到11.1个月，而对照组使用Alpelisib联合Fulvestrant方案的中位无进展生存期仅为5.6个月。这一对比数据突显了Gedatolisib三联疗法的潜在优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179894923","title":"Celcuity公司：Gedatolisib治疗方案总体耐受性良好，不良事件多为低级别","url":"https://stock-news.laohu8.com/highlight/detail?id=1179894923","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179894923?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:15","pubTimestamp":1780402516,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件，Celcuity Inc 在其临床研究中评估的Gedatolisib治疗方案展现出积极的耐受性特征。数据显示，该治疗方案总体上被患者良好耐受，所报告的大多数不良事件严重程度较低，属于低级别范畴。这一发现为后续的临床开发提供了支持性数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113606237","title":"Celcuity公司将于2026年6月2日召开电话会议，讨论Gedatolisib方案针对HR+/HER-晚期乳腺癌的3期Viktoria-1临床试验中PIK3CA突变队列的结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1113606237","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113606237?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:30","pubTimestamp":1780317020,"startTime":"0","endTime":"0","summary":"Celcuity公司计划于2026年6月2日举行一场电话会议，专门探讨其关键候选药物Gedatolisib联合方案在HR+/HER-晚期乳腺癌患者中的最新临床数据。此次会议的核心议题，将聚焦于3期Viktoria-1临床试验中，针对携带PIK3CA基因突变的患者队列所获得的详细结果。该数据的公布，预计将为评估Gedatolisib在这一特定患者群体中的疗效与安全性提供关键洞见，并可能影响未来的治疗策略与监管路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122239009","title":"Celcuity Inc：预计现金、现金等价物、投资及信贷额度提款将支撑运营至2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=1122239009","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122239009?lang=zh_cn&edition=full","pubTime":"2026-05-15 04:04","pubTimestamp":1778789052,"startTime":"0","endTime":"0","summary":"Celcuity Inc 预计，其现有的现金及现金等价物、投资组合，以及通过信贷额度进行的潜在提款，将共同为公司运营提供资金支持，直至2027年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147706263","title":"异动解读 | 新药获FDA优先审评且临床试验扩大，Celcuity盘中大涨6.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147706263","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147706263?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:13","pubTimestamp":1778768010,"startTime":"0","endTime":"0","summary":"Celcuity Inc今日盘中股价大涨6.23%，引起了市场的广泛关注。首先，Celcuity Inc宣布，其针对核心药物Gedatolisib的新药申请已获得美国食品药品监督管理局的优先审评资格，关键审评日期定于2026年7月17日，这标志着该药物在监管审批流程中迈出了关键一步，有望加速上市进程。与此同时，公司另一则公告显示，其针对Gedatolisib作为HR+/HER2-晚期乳腺癌一线疗法的III期Viktoria-2临床试验，将扩大招募范围，将内分泌敏感患者群体也纳入其中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142039438","title":"Celcuity Inc 新药申请获FDA优先审评资格，关键审评日期定于2026年7月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=1142039438","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142039438?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:31","pubTimestamp":1778758282,"startTime":"0","endTime":"0","summary":"Celcuity Inc 宣布，其针对Gedatolisib的新药申请已获得美国食品药品监督管理局的优先审评资格。该申请的处方药用户付费法案目标审评日期定为2026年7月17日。此项决定标志着该药物在监管审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155265476","title":"Celcuity公司Gedatolisib一线治疗HR+/HER2-晚期乳腺癌的III期Viktoria-2试验将扩大至纳入内分泌敏感患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1155265476","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155265476?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:31","pubTimestamp":1778758274,"startTime":"0","endTime":"0","summary":"Celcuity公司宣布，其针对Gedatolisib作为HR+/HER2-晚期乳腺癌一线疗法的III期Viktoria-2临床试验，将扩大招募范围，将内分泌敏感患者群体也纳入其中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145932969","title":"Celcuity公司Viktoria-1三期试验达成主要终点 Pik3CA突变队列无进展生存期获临床意义改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1145932969","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145932969?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:06","pubTimestamp":1777669572,"startTime":"0","endTime":"0","summary":"Celcuity公司宣布，其Viktoria-1三期临床试验在Pik3CA突变患者队列中成功达成主要研究终点。试验数据显示，该队列患者的无进展生存期实现了具有临床意义的显著改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165644166","title":"Celcuity公司宣布Gedatolisib用于HR+/HER2-/PIK3CA野生型晚期乳腺癌的新药申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1165644166","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165644166?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:31","pubTimestamp":1768912276,"startTime":"0","endTime":"0","summary":"Celcuity Inc 宣布，其候选药物Gedatolisib针对HR阳性、HER2阴性且PIK3CA基因为野生型的晚期乳腺癌患者所提交的新药申请，已获得美国食品药品监督管理局的正式受理。此次受理标志着该药物在审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508147715","title":"Celcuity Inc.盘中异动 大幅拉升5.31%报12.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508147715","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508147715?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:34","pubTimestamp":1738596849,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时34分，Celcuity Inc.股票出现波动，股价快速拉升5.31%。截至发稿，该股报12.59美元/股，成交量3.2582万股，换手率0.09%，振幅8.79%。Celcuity Inc.股票所在的生物技术行业中，整体跌幅为0.73%。其相关个股中，Hcw Biologics Inc.、Invivyd, Inc.、Gh Research Plc涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为543.95%、418.49%、343.83%，振幅较大的相关个股有Hcw Biologics Inc.、Invivyd, Inc.、Briacell Therapeutics Corp.，振幅分别为158.16%、75.23%、53.59%。Celcuity Inc.公司简介：Celcuity Inc 是一家致力于开发肿瘤学方向的临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020323340998797904&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020323340998797904&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508120960","title":"Celcuity Inc.盘中异动 大幅上涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508120960","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508120960?lang=zh_cn&edition=full","pubTime":"2025-02-01 00:50","pubTimestamp":1738342225,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日00时50分，Celcuity Inc.股票出现异动，股价急速拉升5.03%。Celcuity Inc.股票所在的生物技术行业中，整体涨幅为1.47%。其相关个股中，Cyclerion Therapeutics, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Geovax Labs Inc C/Wts 29/09/2025涨幅较大，Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.、Silexion Therapeutics Corp较为活跃，换手率分别为2126.43%、1938.99%、182.85%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为80.00%、56.30%、52.24%。Celcuity Inc.公司简介：Celcuity Inc 是一家致力于开发肿瘤学方向的临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201005026a2355b48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201005026a2355b48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506306258","title":"Celcuity Inc.盘中异动 早盘大幅拉升5.28%报12.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506306258","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506306258?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:50","pubTimestamp":1737989438,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时50分，Celcuity Inc.股票出现波动，股价大幅上涨5.28%。截至发稿，该股报12.02美元/股，成交量1.0472万股，换手率0.03%，振幅4.99%。Celcuity Inc.股票所在的生物技术行业中，整体涨幅为1.09%。Celcuity Inc.公司简介：Celcuity Inc 是一家致力于开发肿瘤学方向的临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225038abba6408&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225038abba6408&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503628458","title":"Celcuity Inc.盘中异动 早盘大幅拉升5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503628458","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503628458?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:32","pubTimestamp":1736951529,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时32分，Celcuity Inc.股票出现波动，股价快速拉升5.41%。Celcuity Inc.股票所在的生物技术行业中，整体涨幅为0.77%。其相关个股中，Monte Rosa Therapeutics, Inc.、Exicure, Inc.、Generation Bio Co.涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Oncolytics Biotech Inc.较为活跃，换手率分别为184.95%、52.43%、35.39%，振幅较大的相关个股有Klotho Neurosciences, Inc.、Vincerx Pharma, Inc.、Viracta Therapeutics, Inc.，振幅分别为12.00%、10.72%、9.48%。Celcuity Inc.公司简介：Celcuity Inc 是一家致力于开发肿瘤学方向的临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223209a222fe03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223209a222fe03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503831525","title":"Celcuity Inc.盘中异动 早盘急速跳水5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503831525","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503831525?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:35","pubTimestamp":1736778954,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时35分，Celcuity Inc.股票出现异动，股价急速下跌5.54%。Celcuity Inc.股票所在的生物技术行业中，整体跌幅为1.06%。其相关个股中，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为3379.01%、2095.08%、392.79%，振幅较大的相关个股有Salarius Pharmaceuticals, Inc.、Champions Oncology, Inc.、Phio Pharmaceuticals Corp.，振幅分别为104.79%、102.87%、60.36%。Celcuity Inc.公司简介：Celcuity Inc 是一家致力于开发肿瘤学方向的临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223554a220409d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223554a220409d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502566867","title":"Celcuity Inc.盘中异动 股价大跌5.16%报12.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502566867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502566867?lang=zh_cn&edition=full","pubTime":"2025-01-10 22:47","pubTimestamp":1736520428,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日22时47分，Celcuity Inc.股票出现波动，股价大幅跳水5.16%。截至发稿，该股报12.05美元/股，成交量11.057万股，换手率0.30%，振幅4.06%。Celcuity Inc.股票所在的生物技术行业中，整体跌幅为0.85%。Celcuity Inc.公司简介：Celcuity Inc 是一家致力于开发肿瘤学方向的临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011022470895ff715f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011022470895ff715f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celcuity.com","stockEarnings":[{"period":"1week","weight":0.1253},{"period":"1month","weight":0.1808},{"period":"3month","weight":-0.0416},{"period":"6month","weight":0.0736},{"period":"1year","weight":7.2784},{"period":"ytd","weight":0.0823}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Celcuity Inc.于2011年在明尼苏达州注册成立为一家有限责任公司，并于2017年9月15日在特拉华州重新注册成立。该公司是一家临床阶段的生物技术公司，专注于开发针对实体瘤的靶向疗法。其主要候选药物gedatolisib是一种PI3K/AKT/mTOR通路激酶抑制剂，目前正在进行针对HR+/HER2-晚期乳腺癌及其他适应症的3期临床试验。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.002348},{"month":2,"riseRate":0.555556,"avgChangeRate":-0.027609},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.001524},{"month":4,"riseRate":0.666667,"avgChangeRate":0.07157},{"month":5,"riseRate":0.555556,"avgChangeRate":0.06966},{"month":6,"riseRate":0.666667,"avgChangeRate":0.064311},{"month":7,"riseRate":0.333333,"avgChangeRate":0.163173},{"month":8,"riseRate":0.625,"avgChangeRate":0.016512},{"month":9,"riseRate":0.375,"avgChangeRate":-0.012139},{"month":10,"riseRate":0.555556,"avgChangeRate":0.125622},{"month":11,"riseRate":0.444444,"avgChangeRate":0.071442},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028056}],"exchange":"NASDAQ","name":"Celcuity Inc","nameEN":"Celcuity Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celcuity Inc(CELC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Celcuity Inc(CELC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Celcuity Inc,CELC,Celcuity Inc股票,Celcuity Inc股票老虎,Celcuity Inc股票老虎国际,Celcuity Inc行情,Celcuity Inc股票行情,Celcuity Inc股价,Celcuity Inc股市,Celcuity Inc股票价格,Celcuity Inc股票交易,Celcuity Inc股票购买,Celcuity Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celcuity Inc(CELC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Celcuity Inc(CELC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}